Abstract
Availability of biosimilar drugs in the United States and other regions of the world plays an important role in decreasing drug prices and increasing access to life-enhancing therapies. To ensure safety, efficacy, and bioequivalence of these biologically-derived products, their commercialization pathway is governed by stringent, and sometimes region-specific, clinical and quality requirements. Biosimilars represent a unique class of biopharmaceuticals in which the clinical commercialization pathway is streamlined, but the stringency of analytical characterization remains high. Comprehensive analytical characterization is required to demonstrate analytical similarity of numerous quality attributes between the biosimilar and reference products. In this chapter, the authors present an overarching, yet adaptive, analytical characterization strategy intended to satisfy world-wide regulatory expectations for approval of protein-based biosimilars in key regions of the world with known requirements for marketing authorization. The authors then demonstrate how analytical characterization methods may be managed within a broad and general lifecycle characterization framework. It is the authors’ belief that a carefully designed characterization strategy, such as the one recommended in this chapter, will enable more rapid development of high-quality biosimilar drugs and aid in successfully bringing them to market.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
42 U.S.C. 262 - Regulation of biological products. Available at: https://www.gpo.gov/fdsys/granule/USCODE-2010-title42/USCODE-2010-title42-chap6A-subchapII-partF-subpart1-sec262. Accessed 5 Sept 2017.
Arthur KK, Dinh N, Gabrielson JP. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation. J Pharm Sci. 2015;104:1548–54.
Barnett K, et al. Analytical target profile: structure and application throughout the analytical lifecycle. Pharmacopeial Forum. 2016;42:1–15.
Biologics Price Competition and Innovation Act of 2009. Available at: https://www.fda.gov/downloads/drugs/ucm216146.pdf. Accessed 22 May 2018.
Chon JH, Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. New Biotechnol. 2011;28:458–63.
Dinh NN, Winn BC, Arthur KK, Gabrielson JP. Quantitative spectral comparison by weighted spectral difference for protein higher order structure confirmation. Anal Biochem. 2014;464:60–2.
European Medicines Agency. Guideline on similar biological medicinal products: CHMP 437/04 Rev 1. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 22 May 2018.
FDA. Guidance for industry: process validation: general principles and practices. 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070336.pdf.
Flynn GC, Nyberg GB. Using quality by design principles in setting a control strategy for product quality attributes. In: State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization, Monoclonal antibody therapeutics, vol. 1. Washington, D.C.: ACS Publications; 2014.
Goetze AM, Schenauer MR, Flynn GC. Assessing monoclonal antibody product quality attribute criticality through clinical studies. MAbs. 2010;2:500–7.
Harris RJ, et al. Analytical characterization of monoclonal antibodies: linking structure to function. In: Current trends in monoclonal antibody development and manufacturing. New York: Springer; 2010. p. 193–205. https://doi.org/10.1007/978-0-387-76643-0_12.
ICH Harmonized Tripartite Guideline. Validation of analytical procedures: text and methodology ICH Q2(R1). 2005.
International Conference on Harmonization. ICH Q6B: specifications: test procedures and acceptance criteria for biotechnological/biological products. 2009a. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf. Accessed 22 May 2018.
International Conference on Harmonization. ICH Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process. 2009b. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed 22 May 2018.
International Conference on Harmonization. ICH Q8(R2): pharmaceutical development. 2009c. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf. Accessed 22 May 2018.
International Conference on Harmonization. ICH Q9: quality risk management. 2009d. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf. Accessed 22 May 2018.
International Conference on Harmonization. ICH Q10: pharmaceutical quality system. 2009e. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf. Accessed 22 May 2018.
Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. MAbs. 2010;2:480–99.
Liu YD, van Enk JZ, Flynn GC. Human antibody Fc deamidation in vivo. Biologicals. 2009;37:313–22.
Martin GP, et al. Lifecycle management of analytical procedures: method development, procedure performance qualification, and procedure performance verification. Available at http://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/lifecycle_pdf.pdf. Accessed 22 May 2018.
Schenerman MA, et al. CMC strategy forum report: analysis and structure characterization of monoclonal antibodies. BioProcess Int. 2004;2(2):42–51.
Shukla AA, Wolfe LS, Mostafa SS, Norman C. Evolving trends in mAb production processes. Bioeng Transl Med. 2017;2:58–69.
Teska BM, et al. Comparison of quantitative spectral similarity analysis methods for protein higher-order structure confirmation. Anal Biochem. 2013;434:153–65.
Tsuruta LR, Lopes dos Santos M, Moro AM. Biosimilars advancements: moving on to the future. Biotechnol Prog. 2015;31:1139–49.
U.S. Department of Health and Human Services, Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed 22 May 2018.
U.S. Department of Health and Human Services, Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product: guidance for industry. 2016. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf. Accessed 22 May 2018.
U.S. Department of Health and Human Services, Food and Drug Administration. M4Q: The CTD - quality. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073280.pdf. Accessed 22 May 2018a.
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: statistical approaches to evaluate analytical similarity. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm576786.pdf. Accessed 22 May 2018b.
United States Pharmacopeia. USP <1220> The analytical procedure lifecycle. 2017. 9.
Vandekerckhove K, et al. Rational selection, criticality assessment, and tiering of quality attributes and test methods for analytical similarity evaluation of biosimilars. AAPS J. 2018;20:68.
Declaration of Interest
The authors are employees of KBI Biopharma, Inc., which serves as a contract development and manufacturing organization in the biopharmaceutical industry, including contract analytical testing and manufacturing of biosimilars.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Gabrielson, J.P., Young, J.A., Kendrick, B.S. (2018). Application of an Adaptive Analytical Characterization Strategy to Support Development and Approval of Biosimilars. In: Gutka, H., Yang, H., Kakar, S. (eds) Biosimilars. AAPS Advances in the Pharmaceutical Sciences Series, vol 34. Springer, Cham. https://doi.org/10.1007/978-3-319-99680-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-99680-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99679-0
Online ISBN: 978-3-319-99680-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)